MA53436A - Anticorps anti-cgrp pour patients résistants au traitement - Google Patents

Anticorps anti-cgrp pour patients résistants au traitement

Info

Publication number
MA53436A
MA53436A MA053436A MA53436A MA53436A MA 53436 A MA53436 A MA 53436A MA 053436 A MA053436 A MA 053436A MA 53436 A MA53436 A MA 53436A MA 53436 A MA53436 A MA 53436A
Authority
MA
Morocco
Prior art keywords
treatment
cgrp antibodies
resistant patients
patients
resistant
Prior art date
Application number
MA053436A
Other languages
English (en)
Inventor
Sheena Kaur Aurora
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53436A publication Critical patent/MA53436A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA053436A 2018-08-22 2019-08-21 Anticorps anti-cgrp pour patients résistants au traitement MA53436A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862721258P 2018-08-22 2018-08-22

Publications (1)

Publication Number Publication Date
MA53436A true MA53436A (fr) 2021-12-01

Family

ID=67851230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053436A MA53436A (fr) 2018-08-22 2019-08-21 Anticorps anti-cgrp pour patients résistants au traitement

Country Status (5)

Country Link
US (1) US20210340230A1 (fr)
EP (1) EP3840836A1 (fr)
JP (1) JP2021534197A (fr)
MA (1) MA53436A (fr)
WO (1) WO2020041468A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
US10392434B2 (en) 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10392434B2 (en) * 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Also Published As

Publication number Publication date
JP2021534197A (ja) 2021-12-09
WO2020041468A1 (fr) 2020-02-27
EP3840836A1 (fr) 2021-06-30
US20210340230A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA47694A (fr) Anticorps anti-tigit
MA43028A (fr) Anticorps bispécifiques pour pd1 et tim3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA47268A (fr) Anticorps anti-gpc3
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA46057A (fr) Anticorps anti-ctla4
MA52366A (fr) Anticorps anti-tl1a optimisés
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA52212A (fr) Anticorps multivalent
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
MA52152A (fr) Anticorps
MA43587A (fr) Arnm thérapeutiques codant pour des anticorps anti-ctla-4
IL282641A (en) Single domain antibodies that bind human serum albumin
MA49250A (fr) Nouveaux anticorps anti-cd3
MA51134A (fr) Anticorps anti-alpha-synucléine
MA51212A (fr) Anticorps neutralisant les polyomavirus
MA39708A (fr) Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA53322A (fr) Anticorps procoagulants améliorés
MA52545A (fr) Anticorps pour radionucléides chélatés
MA56466A (fr) Anticorps anti-epha4